Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Income from Continuing Operations (2016 - 2026)

Sunshine Biopharma filings provide 13 years of Income from Continuing Operations readings, the most recent being 5063102.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 16.86% to 5063102.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1228677.0, a 9.43% decrease, with the full-year FY2025 number at 1228677.0, down 9.43% from a year prior.
  • Income from Continuing Operations hit 5063102.0 in Q4 2025 for Sunshine Biopharma, up from 883820.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5063102.0 in Q4 2025 to a low of 23512315.0 in Q4 2022.
  • Median Income from Continuing Operations over the past 5 years was 1217018.5 (2022), compared with a mean of 2055084.1.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 6461.84% in 2021 and later skyrocketed 446.59% in 2024.
  • Sunshine Biopharma's Income from Continuing Operations stood at 667116.0 in 2021, then plummeted by 3624.47% to 23512315.0 in 2022, then surged by 94.68% to 1250024.0 in 2023, then skyrocketed by 446.59% to 4332476.0 in 2024, then rose by 16.86% to 5063102.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 5063102.0 (Q4 2025), 883820.0 (Q3 2025), and 1770834.0 (Q2 2025) per Business Quant data.